Technical Analysis for CTSO - Cytosorbents Corporation

Grade Last Price % Change Price Change
D 0.97 9.78% 0.09
CTSO closed up 9.78 percent on Monday, March 18, 2024, on 81 percent of normal volume. It ran into resistance at its 50 day moving average.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Bullish Engulfing Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
MACD Bearish Signal Line Cross Bearish 9.78%
New 52 Week Closing Low Bearish 9.78%
Expansion Pivot Sell Setup Bearish Swing Setup 9.78%
Volume Surge Other 9.78%
Below Lower BB Weakness 9.78%

   Recent Intraday Alerts

Alert Time
Up 10% about 17 hours ago
Rose Above Previous Day's High about 18 hours ago
60 Minute Opening Range Breakout about 19 hours ago
Rose Above Lower Bollinger Band about 19 hours ago
Up 5% about 19 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cytosorbents Corporation Description

CytoSorbents Corporation, a development stage company, is engaged in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The company develops its adsorbent polymer technology for various applications in the medical field, primarily to provide blood purification for acute and chronic health complications associated with blood toxicity. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; for the adjunctive therapy in other critical care applications, including acute respiratory distress syndrome, severe burn injury, trauma, and pancreatitis; to prevent and treat organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and for the prevention and treatment of post-operative complications of cardiopulmonary bypass surgery. The company is also developing HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. CytoSorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Clinical Medicine Disease Imaging Medical Equipment Kidney Disease Dysfunction Interventional Radiology Membrane Technology Radiology Cytokine Toxins Perfusion Blood Plasma Bypass Organs Renal Dialysis Transfusion Medicine Acute Respiratory Distress Syndrome Sepsis Blood Products Bypass Surgery Cardiopulmonary Bypass Pancreatitis Respiratory Distress Adjunctive Therapy Cardiopulmonary Bypass Surgery Respiratory Distress Syndrome Toxic Chemicals

Is CTSO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.29
52 Week Low 0.84
Average Volume 165,989
200-Day Moving Average 1.99
50-Day Moving Average 0.98
20-Day Moving Average 0.98
10-Day Moving Average 0.99
Average True Range 0.06
RSI (14) 46.52
ADX 18.13
+DI 12.79
-DI 22.40
Chandelier Exit (Long, 3 ATRs) 0.86
Chandelier Exit (Short, 3 ATRs) 1.06
Upper Bollinger Bands 1.05
Lower Bollinger Band 0.91
Percent B (%b) 0.39
BandWidth 14.81
MACD Line -0.02
MACD Signal Line -0.01
MACD Histogram -0.0018
Fundamentals Value
Market Cap 50.4 Million
Num Shares 52.2 Million
EPS -0.53
Price-to-Earnings (P/E) Ratio -1.82
Price-to-Sales 1.44
Price-to-Book 2.87
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.13
Resistance 3 (R3) 1.12 1.06 1.10
Resistance 2 (R2) 1.06 1.01 1.06 1.09
Resistance 1 (R1) 1.01 0.99 1.03 1.02 1.09
Pivot Point 0.95 0.95 0.96 0.95 0.95
Support 1 (S1) 0.90 0.90 0.92 0.91 0.85
Support 2 (S2) 0.84 0.88 0.84 0.84
Support 3 (S3) 0.79 0.84 0.83
Support 4 (S4) 0.80